Kyntra Bio CFO Sells 60 Shares Amid Insider Sales Wave as Stock Tumbles 38% YTD

Insider Selling in a Volatile Period

On March 6, 2026 Chief Financial Officer DeLucia David sold 60 shares of Kyntra Bio Inc. Common Stock at $6.84 per share, a price just below the company’s current market close of $7.34. The sale coincided with the issuer withholding shares to satisfy a tax obligation triggered by the vesting of restricted stock units. While the transaction size is modest relative to the company’s total outstanding shares, the timing—amid a broader wave of insider sales by CEO Wettig Thane—raises questions about insider confidence during a period of declining share price and negative earnings guidance.

What Investors Should Take Away

Kyntra’s share has already fallen 38 % year‑to‑date and is trading roughly mid‑way between its 52‑week low of $4.85 and high of $12.60. The recent insider sales, coupled with a price dip of 0.03 % on the day of the transaction, suggest that senior executives may be rebalancing their personal portfolios rather than signaling a fundamental shift in company prospects. Nevertheless, the presence of a negative price‑earnings ratio and the pending Phase 1b/2 data from the FG‑3246 study indicate that investors should watch both clinical outcomes and any subsequent guidance before committing to a long‑term position.

DeLucia David’s Insider Profile

DeLucia’s transaction history is sparse but telling. In early February she purchased 26,000 shares of stock options at no cost, reflecting a strong belief in the company’s long‑term potential. Her March sale of 60 shares, though small, is consistent with a routine tax‑related disposal rather than an aggressive divestment. Compared with CEO Wettig Thane’s two sales of 277 and 259 shares on the same day, DeLucia’s activity appears more conservative and aligned with routine corporate compliance rather than a signal of impending downturns.

Strategic Implications for the Company

If the forthcoming Phase 1b/2 results confirm the efficacy of FG‑3246 in combination therapy, the company could see renewed investor enthusiasm, potentially offsetting the current negative sentiment reflected in a 97 % social media buzz. Until then, the modest insider sales are unlikely to materially alter the company’s capital structure or strategic trajectory. Investors should remain focused on the clinical milestones and any forthcoming earnings guidance rather than individual insider trades of this scale.